Comparison · NCT00385580-4a5cf730
Dasatinib 100 mg Once Daily (QD) vs Dasatinib 100 mg or 70 mg Twice Daily (BID): Number of Participants With Increase in PSA Doubling Time
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Dasatinib 100 mg Once Daily (QD) vs Dasatinib 100 mg or 70 mg Twice Daily (BID): Number of Participants With Increase in PSA Doubling Time. Trial comparisons, record NCT00385580-4a5cf730. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT00385580-4a5cf730
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.895 | 0.759 | 0.958 | wilson | |
| Risk in group 2 | 0.78 | 0.633 | 0.88 | wilson | |
| Risk difference, group 1 minus group 2 | 0.114 | -0.0543 | 0.275 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 1.15 | 0.943 | 1.39 | log | |
| Odds ratio, group 1 over group 2 | 2.39 | 0.669 | 8.54 | log | |
| Number needed to treat, for one more participant with the outcome on Dasatinib 100 mg Once Daily (QD) than on Dasatinib 100 mg or 70 mg Twice Daily (BID) | 8.75 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Dasatinib 100 mg Once Daily (QD) | Participants were administered an oral dose of 100 mg dasatinib tablet QD. Participants continued to receive the study drug as long as tolerated or until progressive disease (PD), defined as appearance of new lesion/s, or \>=20% increase in the sum of the longest diameter (LD) of target lesions, relative to the smallest sum LD recorded since treatment start, or unequivocal progression of existing non-target lesions. | 34 | 38 | OG000 |
| Group 2 | Dasatinib 100 mg or 70 mg Twice Daily (BID) | Participants were administered an oral dose of 100 mg dasatinib tablet BID for a total daily dose (TDD) of 200 mg which was later decreased to 70 mg BID for a TDD of 140 mg. Of the 47 treated participants in the BID group, 25 received 100 mg and 22 received 70 mg of dasatinib as their starting doses. Participants continued to receive the study drug as long as tolerated or until progressive disease (PD), defined as appearance of new lesion/s, or \>=20% increase in the sum of the longest diameter (LD) of target lesions, relative to the smallest sum LD recorded since treatment start, or unequivocal progression of existing non-target lesions. | 32 | 41 | OG001 |
Source ClinicalTrials.gov
Outcome
- Type
- SECONDARY
- Title
- Number of Participants With Increase in PSA Doubling Time
- Description
- PSA is a marker of prostate cancer. PSA doubling time is defined as log 2 divided by the slope of the log PSA line. An increase in PSA doubling time indicates improvement in anti-tumor activity.
- Time frame
- Prior to treatment with the study drug, Week 4, Week 8, Week 12 and every 4 weeks thereafter.
- Population
All PSA response-evaluable participants: participants who had 2 or more pre-treatment PSA measurements and at least 2 on-study PSA measurements and positive log slope pre-treatment and on-study measurements.
Source ClinicalTrials.gov
Trial
- Title
- Phase II Study of Dasatinib (BMS-354825) for Androgen-deprived Progressive Prostate Cancer
- NCT number
- NCT00385580
- Phases
- PHASE2
- Conditions
- Prostate Cancer
- Interventions
- dasatinib, dasatinib
- Lead sponsor
- Bristol-Myers Squibb
- Results first posted
- 2011-03-01
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT00385580?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT00385580-4a5cf730